TITLE:
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

CONDITION:
HIV Infections

INTERVENTION:
Vesnarinone

SUMMARY:

      To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with
      advanced HIV disease.
    

DETAILED DESCRIPTION:

      Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least
      seven patients at a given dose level must have completed 4 weeks of treatment before dose is
      escalated in subsequent patients.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and other
             opportunistic infections.

          -  Acyclovir for up to 14 days for acute herpes outbreaks.

        Patients must have:

          -  Documented HIV infection.

          -  CD4 count 50 - 300 cells/mm3.

          -  No active opportunistic infections.

          -  No fever, diarrhea, or Herpes zoster.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Clinically significant current cardiac disease, including patients who exhibit long
             QTC syndrome on EKG screening and who have an abnormal cardiothoracic ratio on chest
             x-ray at baseline.

          -  Active malignancy (other than cutaneous Kaposi's sarcoma or cutaneous basal cell
             carcinoma or in situ carcinoma of the cervix).

        Concurrent Medication:

        Excluded:

          -  Antiretroviral agents, including ddI, ddC, AZT, and d4T.

          -  Immunosuppressive agents.

          -  Investigational HIV drugs/therapies including vaccines.

          -  Interferon or other immunomodulating agents.

          -  Corticosteroids (other than topical).

          -  Hematopoietins.

          -  Megestrol acetate.

          -  Agents known to cause neutropenia.

          -  Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg
             sulfamethoxazole thrice weekly.

          -  Cytotoxic chemotherapy.

        Concurrent Treatment:

        Excluded:

          -  Radiation therapy.

        Patients with the following prior conditions are excluded:

          -  Prior history of cardiac disease.

          -  History of agranulocytosis or severe (grade 3 or worse) drug-induced neutropenia or
             documented abnormalities in granulocyte function.

        Prior Medication:

        Excluded:

          -  AZT, ddI, ddC, d4T, or other nucleoside analog antiretroviral therapy within 14 days
             prior to study entry.

          -  Prior cytotoxic chemotherapy.

          -  Acyclovir for herpes prophylaxis within 48 hours prior to study entry.

        Prior Treatment:

        Excluded within 30 days prior to study entry:

          -  Erythropoietin, transfusion, or blood product use.

          -  Radiation therapy (including electron beam irradiation). Active use of illicit drugs
             (specifically cocaine, amyl nitrate, heroin, and other cardioactive agents).
      
